MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
Cell Therapy Revenue: $6.5 million, a 39% year-over-year increase. Drug Discovery Revenue: $1.6 million, a 14% year-over-year decline. Instrument Revenue: $1.8 million, compared to $1.7 million in Q3 2023. Lease Revenue: $2.5 million, compared to $2.4 million in Q3 2023. Processing Assembly (P/A) Revenue: $3.4 million, up from $2.2 million in the prior year quarter. Gross Margin: 76% in Q3 2024, down from 90% in Q3 2023. Non-GAAP Adjusted Gross Margin: 85% in Q3 2024, compared to 88% in Q3 2023. Total Operating Expenses: $20.3 million, down from $21.2 million in Q3 2023. Cash and Cash Equivalents: $196.6 million at the end of Q3 2024, with no debt. Year-End Cash Guidance: Expected to end 2024 with $185 million in cash equivalents and investments. Core Revenue Growth Guidance: Increased to at least 5% growth compared to 2023. SPL Program Related Revenue Guidance: Approximately $6 million in 2024. Warning! GuruFocus has detected 6 Warning Signs with MXCT. Rele
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- This MaxCyte Insider Increased Their Holding In The Last Year [Yahoo! Finance]Yahoo! Finance
- MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsGlobeNewswire
- MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance [Yahoo! Finance]Yahoo! Finance
- MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceGlobeNewswire
MXCT
Earnings
- 11/6/24 - Beat
MXCT
Sec Filings
- 11/13/24 - Form SC
- 11/8/24 - Form SC
- 11/6/24 - Form 10-Q
- MXCT's page on the SEC website